Randomized, prospective studies comparing BUCY to TBI conditioning regimens for allogeneic bone marrow transplantation have yielded conflicting results. We investigated the overall survival, the disease-free survival and the toxicities of BUCY vs TBI-based regimens by conducting a meta-analysis of all published, randomized, prospective trials comparing these regimens. Five studies were analyzed. We evaluated six endpoints: survival, disease-free survival, veno-occlusive disease (VOD) of the liver, acute GVHD, chronic GVHD, and interstitial pneumonitis. We combined individual study results using a random effects model. Survival and disease-free survival were better with TBI-based regimens than with BUCY, but these differences were not statistically significant (survival odds ratio 1.4, 95% confidence interval 0.9-2.2, P = 0.09; disease-free survival odds ratio 1.2, 95% confidence interval 0.7-2.1, P = 0.44). A power analysis indicated that BUCY was unlikely to have a clinically relevant survival or disease-free survival advantage. The power analysis could not exclude the possibility of such an advantage for TBI-based regimens. A significantly greater incidence of VOD occurred with BUCY (odds ratio 2.5, 95% confidence interval 1.2-5.2, P = 0.02). For the other side-effects, there were no significant differences. We concluded that TBI-based regimens cause less VOD than BUCY and are at least as good for survival and disease-free survival. Keywords: bone marrow transplantation,; busulfan; cyclophosphamide; whole-body irradiation; meta-analysis Allogeneic bone marrow transplantation, preceded by conditioning with high-dose CY and total-body irradiation (TBI), has been used since the 1970s to treat patients suffering from acute and chronic myeloid leukemia. Bone marrow transplantation may fail from relapse, graft failure or complications including graft-versus-host disease (GVHD), interstitial pneumonitis and veno-occlusive disease (VOD) of the liver. Investigators have attempted to modify the Correspondence: JJ Dillon, 5841 S Maryland Ave MC 5100, Chicago, IL 60637, USA Received 2 December 1997; accepted 1 April 1998 standard CY/TBI regimen to reduce toxicity and improve long-term remission.
standard CY/TBI regimen to reduce toxicity and improve long-term remission. 1 To this end, a BU-containing, highdose CY (BUCY) regimen was developed.
Retrospective studies of BUCY have suggested that leukemia ablation is similar or even higher than with regimens containing TBI. [1] [2] [3] VOD has been reported to occur more frequently among some, 4 but not all, 5 BU-treated patients in these retrospective series. In contrast, interstitial pneumonitis has been reported to occur more frequently among TBI-treated patients. 4, 6, 7 Randomized prospective studies comparing TBI-based regimens to BUCY have yielded conflicting results for both survival and toxicities.
To determine which regimen was superior, we conducted a meta-analysis of the randomized, prospective trials. [8] [9] [10] [11] [12] We evaluated six endpoints: overall survival, disease-free survival, acute GVHD, chronic GVHD, VOD of the liver and interstitial pneumonitis. These toxicities were chosen because they occur frequently and cause significant morbidity and mortality. The following is an account of our findings.
Methods
We identified trials comparing BUCY with TBI-based regimens from Medline (1966 Medline ( to 1996 and from references in published articles. Only prospective, randomized, controlled trials in which conditioning regimens using TBI were compared to conditioning regimens using BUCY for allogeneic bone marrow transplantation were included. The primary outcomes were survival and disease-free survival. In addition, we compared the toxicities of the two regimens, specifically grade II-IV acute GVHD, chronic GVHD, VOD of the liver and interstitial pneumonitis.
Effect sizes were calculated from summary data (2 × 2 tables). Study weights were calculated as:
where N 1-4 are the marginal totals from the 2 × 2 tables and N total is the total number of subjects in each study. 13 Effect sizes, in standard deviations (s.d.) were calculated as Z p /(weight 1/2 ), where Z p is the value of the two-tailed standard normal distribution, evaluated at p; p is the 2 × 2 table probability, calculated using Fischer's exact test. Odds ratios were calculated as e −effect size and were less than 1 if the adverse outcome occurred less frequently among BUCY-treated patients.
We combined individual studies using a random effects model. 14 Heterogeneity and between-studies variances were calculated using the Q statistic.
14 The statistical significance of outlier results was tested by contrasting individual study results with the mean of all other studies 15 under a null hypothesis of no difference among effect sizes, using the Dunn-Sidak method 16 to correct for k comparisons, where k is the number of studies.
We performed sensitivity analysis by recalculating the results after dropping each of the studies. In addition, to test whether the relative effects of BUCY and TBI-based regimens differed for different disease stages, we stratified the outcomes by disease stage, early or late, using a mixed effects model 17 and calculated the statistical significance of stratification. We defined early disease as CML in first chronic phase or AML or ALL in first remission. Late disease included all patients beyond these points.
To assess the power of the meta-analysis, we calculated, for each outcome, the probability of a 25% odds-ratio improvement over the alternative regimen. This was calculated from the mean effect size and its standard error using the one-tailed standard normal distribution. There is no standard definition of a clinically relevant effect; the choice of a 25% improvement represented clinical judgment.
All tests were two-tailed, except as noted. Fischer's exact test was calculated using SAS. Other calculations were made using Quattro Pro for Windows version 5.0.
Results
We identified five prospective, randomized, controlled trials comparing TBI-based regimens to BUCY. [8] [9] [10] [11] [12] No studies meeting these criteria were excluded. Table 1 lists the treatment regimens and initial patient characteristics. The total number of subjects was 652, of whom 314 received TBI and 338 received BUCY.
As shown in Figure 1 , TBI-based regimens were superior for both survival and disease-free survival, but the advan- Odds ratio tages over BUCY were not statistically significant (odds ratio, 1.4; 95% confidence interval, 0.9-2.2; P = 0.09 for survival; odds ratio, 1.2; 95% confidence interval, 0.7-2.1; P = 0.44 for disease-free survival).
The outcomes for acute GVHD, chronic GVHD, VOD and interstitial pneumonitis are displayed in Figures 2 and 3. VOD was significantly less common among TBI-treated patients (odds ratio, 2.5; 95% confidence interval, 1.2-5; P = 0.02). The other toxicities did not differ significantly (odds ratio, 0.9; 95% confidence interval, 0.6-1.2; P = 0.44 for acute GVHD; odds ratio, 1.1; 95% confidence interval, 0.8-1.6; P = 0.58 for chronic GVHD; odds ratio, 0.9; 95% confidence interval, 0.5-1.6; P = 0.66 for interstitial pneumonitis).
Statistically significant heterogeneity (statistically significant between-study variance) was present only for disease-free survival (Q = 9.9, P = 0.04). Non-statistically significant heterogeneity (meaning that the random effects Odds ratio model used a value greater than 0 for the between-study variance) was present for survival (Q = 6.1, P = 0.19) and VOD (Q = 3.1, P = 0.38). No study was a statistical outlier for any outcome. Sensitivity analysis was performed to determine whether eliminating any single study significantly altered the results. Dropping the Blume study led to a significant survival advantage for TBI (odds ratio, 1.6; 95% confidence interval, 1.1-2.5; P = 0.03). Dropping the Blume study, the Blaise study or the Ringden study eliminated the statistical significance of the VOD difference. Dropping no other study changed the result for any outcome. Stratifying for early vs late disease was not statistically significant for any outcome. The Clift study was not included in the VOD analysis because the overall incidence of VOD was not reported. The Clift study did report the incidence of fatal VOD (there was none in either group); including the Clift study in our analysis, using fatal VOD as the outcome for this study, did not change the VOD results.
The power analysis (Table 2) indicated that BUCY was unlikely to have a clinically relevant advantage over TBIbased regimens for survival, disease-free survival, VOD or chronic GVHD; we could not rule out such an advantage for acute GVHD or interstitial pneumonitis. TBI-based regimens are unlikely to have a clinically relevant advantage over BUCY for acute GVHD; we could not rule out such an advantage for the other outcomes.
Discussion
We conducted this meta-analysis to compare the outcomes and adverse effects of TBI-containing regimens to those of BU-containing regimens. Combining the available information augmented statistical power, reconciled conflicting outcomes and allowed calculation of the likelihood that outcomes differed more than would be expected from chance alone. Meta-analysis does not improve the quality of the underlying clinical data; this meta-analysis benefitted from being based upon five, large, prospective, randomized, controlled trials.
The populations, institutions, treatments and follow-up times differed among the studies analyzed. Such differences are inherent to the medical literature and are the greatest challenge and limitation of meta-analysis. We managed these differences, in part, with a random effects model. Random effects means that differences among study outcomes were assumed to result both from chance and from underlying differences among the studies. The alternative, fixed effects, would have assumed that differences among study outcomes resulted from chance alone. Statistical significance is more difficult to achieve under random effects, but significant results are likely to be more broadly applicable.
Incorporating study-design differences into the model, using stratification or regression, is often superior to accounting for such differences as random effects. The mixed effects model that we used is a random effects model to which one or more additional, explanatory variables have been added. With only five studies, and thus limited power for analyzing additional variables, we decided to incorporate only one design variable and chose to stratify by disease status, early vs late. This stratification variable was not sig- Probabilities greater than 5% indicate that a clinically relevant advantage cannot be ruled out, statistically, from the data analyzed (with clinically relevant defined as a 25% odds ratio difference).
nificant for any outcome (meaning that the relative risks, BUCY-treated patients vs TBI-treated patients, were not significantly affected by disease status, not that the prognosis for individuals with early disease was the same as that for those with late disease) and was dropped from the final analysis. We can neither rule in nor rule out the possibility that other subgroups, for example, lymphoid vs myeloid leukemias, may be important. This meta-analysis provides the first demonstration, from prospective, randomized, controlled data, that VOD is more likely with BUCY-based regimens than with TBI-based regimens. The overall incidence of VOD was 9% with BUCY and 3% with TBI. Retrospective series have reported incidences of VOD ranging from 19 to 54%. 4, 5, 18, 19 A recent, retrospective, matched-pair study also found that VOD was more common among BUCY-treated patients. 20 This study also suggested that pre-transplant BUCY and post-transplant methotrexate may be synergistic in promoting VOD. Our data are insufficient to determine whether such synergy exists, however, the relative risk for VOD was not significantly lower in the Blume study, the only study that did not use methotrexate, than in the other studies.
Our study argues against (but, by power analysis, cannot rule out) the suggestion from retrospective series that interstitial pneumonitis is significantly more frequent among TBI-treated patients. The overall incidence of interstitial pneumonitis was 12% with BUCY and 14% with TBI. The incidence has ranged from 12 to 65% in retrospective series. 4, 6, 7, 20, 21 Lung shielding has been reported to reduce the incidence of interstitial pneumonitis in TBI-based regimens. 7 One possible explanation for the lack of an increased incidence of interstitial pneumonitis in our analysis is the use of lung shielding in all of the studies that we analyzed for this outcome.
BUCY-based and TBI-based regimens did not differ statistically for survival or disease-free survival. Sixty per cent of the BUCY-treated patients and 68% of the TBI-treated patients survived. For disease-free survival, the corresponding success rates were 55 and 60%. The power calculation suggested that TBI-based regimens were at least as good (with 'as least as good' defined as the probability of a 25% or greater odds ratio advantage or the alternative being less than 0.05) as BUCY-based regimens for these two outcomes, but could not exclude the possibility that TBI is superior.
Sensitivity analysis suggested that TBI-based regimens would have been significantly better for survival if the Blume study, the only study that favored BUCY, had been excluded. This does not mean that the Blume study was a statistical outlier and in fact it was not (P = 0.54). The Blume study used etoposide in the TBI arm while all of the other studies used cytoxan; an argument can be made for excluding it on this basis. We did not do so because it met our inclusion criteria. The trade-off is between statistical power and methodologic uniformity. Reducing either is disadvantageous and there is no universally correct solution.
Excluding any one of the three studies that favored TBI (Blume, Blaise or Ringden) would have eliminated the statistical significance of VOD. This was primarily a power issue, as the number of cases of VOD was limited. No study favored BUCY for VOD.
While our analysis tended to favor TBI, recently published data suggests that secondary malignancies may be more common among patients treated with this modality. 22 The follow-up times in the studies analyzed were insufficient to evaluate late complications such as this. Longer follow-up times will be useful for more fully defining the roles of TBI and BUCY in transplantation.
We conclude that TBI-based regimens cause less VOD than BUCY-based regimens and are at least as good for survival and disease-free survival. Further, while BUCY is unlikely to have a clinically relevant survival or diseasefree survival advantage over TBI, we can neither confirm nor rule out such an advantage for TBI.
